Pharmaceutical Sciences

EDUCATION

• PhD, SUNY Upstate Medical University

PREVIOUS POSITIONS/APPOINTMENTS

• Research Associate, Johns Hopkins University

• Postdoctoral Fellow, Johns Hopkins University

ACADEMIC/RESEARCH INTERESTS

约70%的雌激素受体(ER)阳性乳腺癌通过各种内分泌治疗显著降低了浸润性乳腺癌的风险. 尽管他莫昔芬和芳香酶抑制剂具有相对安全性和显著的抗肿瘤和化学预防活性, 许多最初有反应的乳腺肿瘤会产生耐药性并最终复发.

我目前的研究方向是探讨内分泌耐药乳腺癌与肿瘤微环境之间串扰中导致内分泌耐药的分泌组.

我的实验室的长期任务是了解内分泌抵抗过程的步骤，以开发有效预防和治疗内分泌抵抗性乳腺癌的治疗方法. 我研究的最终目标是将治疗方法引入临床，提高转移性乳腺癌患者的生存率.

COURSES TAUGHT

• Molecular Biology (undergraduate)
• Pharmaceutical Sciences Research Experience (undergraduate)
• Thesis I & II (undergraduate)
• Pharmacology & Molecular Genetics of Cancer (graduate)
• Pharmaceutical Sciences Journal Club (graduate)

HONORS AND ACHIEVEMENTS

• NIH grant R15 CA271221 (PI)
• NIH grant R15 CA287244 (Collaborator)

ACPHS COMMITTEES

• ACPHS Research Committee
• Faculty Senate
• Institutional Biosafety Committee (IBC)
• MS Pharmaceutical Sciences Admissions Committee

SELECTED PUBLICATIONS

Pandithar S, Galke D, Akume A, Belyakov A, Lomonaco D, Guerra AA, Park J, Reff O， Jin K. CXCL1在内分泌抵抗性乳腺癌和成纤维细胞之间的串扰中的作用. Mol Biol Rep. 2024 Feb 23;51(1):331. doi: 10.1007/s11033-023-09119-4. PubMed PMID: 38393465; PubMed Central PMCID: PMC10891235.

Blakely B, Shin S, Jin K. 雌激素受体阳性乳腺癌的治疗策略综述. Biochem Pharmacol. 2023 Jun;212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 Apr 15. Review. PubMed PMID: 37068524; PubMed Central PMCID: PMC10394654.

Smrekar K, Belyakov A, Jin K. 三阴性乳腺癌与微环境的串扰. Oncotarget. 2023 Mar 31;14:284-293. doi: 10.18632/oncotarget.28397. Review. PubMed PMID: 36999995; PubMed Central PMCID: PMC10064880.

Malone MK, Smrekar K, Park S, Blakely B, Walter A, Nasta N, Park J, Considine M, Danilova LV, Pandey NB, Fertig EJ, Popel AS, Jin K. TNBC微环境中基质细胞分泌的细胞因子作为癌症治疗的潜在靶点. Cancer Biol Ther. 2020 Jun 2;21(6):560-569. doi: 10.1080/15384047.2020.1739484. Epub 2020 Mar 26. PubMed PMID: 32213106; PubMed Central PMCID: PMC7515526.

Jin K, Pandey NB, Popel AS. 同时阻断IL-6和CCL5信号通路协同抑制三阴性乳腺癌生长和转移. Breast Cancer Research 2018 Jun 14;20(1):54. (corresponding author).

Norton KA, Jin K, Popel AS. 模拟三阴性乳腺癌异质性:基质巨噬细胞的作用, fibroblasts and tumor vasculature. Journal of Theoretical Biology 2018 Sep 7;452:56-68.

Johng D, Torga G, Ewing CM, Jin K, Norris JD, McDonnell DP, Isaacs WB. HOXB13与MEIS1的相互作用改变前列腺癌的增殖和基因表达. Prostate2018 Dec 17. doi: 10.1002/pros.23747. [Epub ahead of print].

Malone MS, Smrekar K, Dnilova L, Considine M, Fertig E, Park S, Blakely B, Walter A, Nasta N, Park J, Jin K, Popel A. TNBC微环境中基质细胞分泌的细胞因子作为癌症治疗的潜在靶点:实验和生物信息学预测. Molecular Cancer Research 2018. (corresponding author, in review).

Northon KA, Jin K, and Popel AS. 模拟三阴性乳腺癌异质性:基质巨噬细胞的作用, fibroblasts and tumor vasculature.  J Theor Biol. 2018 Sep 7;452:56-68.

Jin K, Pandey NB and Popel AS. 马拉维洛克联合托珠单抗对小鼠异种移植瘤模型TNBC肿瘤生长和转移的协同作用. Breast Cancer Research. 2018 Jun 14;20(1):54. (Corresponding author)

Jin K, Pandey NB and Popel AS. TNBC和基质成分之间的串扰通过分泌因子增强细胞运动，可被CXCR抑制剂减弱. Oncotarget. 2017 Jul 21;8(36) :60210-6022. (Corresponding author)

Merino VF, Cho S, Liang X, Park S, Jin K, Chen Q, Pan D, Zahnow CA, Rein AR, Sukumar S. Inhibitors of STAT3, β-catenin, 和IGF-1R使小鼠pik3ca突变乳腺癌对PI3K抑制剂敏感. Mol Oncol. 2017 May;11(5):552-566.

Errico MC, Jin K, Carè A, Sukumar S. The widening sphere of influence of HOXB7 in solid tumors. Cancer Res. 2016 May 15;76(10):2857-62.

Yoshida K*, Jin K*, Hong S, Park S, Huso D, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F, Morgenstern A, Sgouros G, Sukumar S. HER-2靶向α -粒子放射核素在人乳腺癌临床前模型中的原位导管癌的有效治疗. Oncotarget. 2016 Apr 23. (*Contributed equally).

Jin K and Sukumar S. HOX基因:抵抗选择性内分泌反应调节剂的主要因素. 2016. BBA-Cancer review. 1865(2):105-110.

Nguyen KN, Merino V, Jin K, Hillocks Y, Zhang Z, Sadik H, Korangath P, Han L, Ordentlich P, Connolly R, Stearns V, Brodie A and Sukumar S. 沉默维甲酸受体- β的再激活和恩替司他对乳腺癌化疗的增强作用——临床前验证和分子机制. 2016. Cancer Res. 2016 Apr 1;76(7):2013-24.

Jin K and Sukumar S. HOXB7蛋白在内分泌抵抗性乳腺癌中的关键作用. 2015. Oncoscience. 15;2(11):917-9.

Jin K, Park S, Teo W, Korangath P, Cho S, Yoshida T, Györffy B, Goswami C, Nakshatri H, Cruz L, Zhou W, Ji H, Su Y, Ekram M, Polyak K, and Sukumar S. HOXB7是HER2和多种ER靶基因激活导致内分泌抵抗的ERα辅助因子. 2015, Cancer discovery. Sep;5(9):944-59.

Liu S, Jin K，傅军，杰成，张辉，冯森，Reissman D，王强，Sukumar S，陈辉. HOXB7通过激活转化生长因子-β信号通路促进肿瘤进展. 2015, Cancer Res. 15;75(4):709-19.

Lee E, Fertigc EJ, Jin K, Sukumar S, Pandey NB and Popel AS. 乳腺癌细胞教育淋巴内皮细胞在转移前壁龛促进转移. 2014, Nature Communications, 2;5:4715.

Shah N*, Jin K*, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C and Sukumar S. HOXB13通过抑制ERα和诱导IL-6表达介导人乳腺癌的他莫昔芬耐药和侵袭性. 2013, Cancer Res. 73(17):5449-58. (*Contributed equally)

Wu X, Ellmann S, Rubin E, Gil M, Jin K, Han L, Chen H, Kwon EM, Guo J, Ha HC and Sukumar S. PARP-1的ADP核糖基化抑制HOXB7的转录活性. 2012, PLoS One. 7(7):e40644.

Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T and Sukumar S. HOXB7蛋白通过激活EGFR通路使乳腺癌细胞对他莫昔芬产生抗性. 2012, Proc Natl Acad Sci U S A. 21:109(8):2736-41.

Jin K and Sukumar S. BRCA1: linking HOX to breast cancer suppression. 2010, Breast Cancer Res. 12(4):306.

Jin K and Sukumar S. Clonal selection in tamoxifen resistance. 2010, Cancer Biol Ther. 9(9):717-24.

Jin K, Ewton DZ, Park S, Hu J and Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. 2009, J Biol Chem. 284(34):22916-25.

Jin K, Park S, Ewton DZ and Friedman E. 存活激酶Mirk/Dyrk1B是胰腺癌中致癌K-ras的下游效应物. 2007, Cancer Res. 67(15):7247-55.

Jin K, Lim S, Mercer SE and Friedman E. 存活激酶Mirk/dyrk1B通过Rac1-MKK3信号通路被激活. 2005, J Biol Chem. 280(51):42097-105.

Jee B, Jin K, Hahn JH, Song HG and Lee H. 转移抑制因子KAI1/CD82通过src依赖途径诱导人前列腺癌细胞的同型聚集. 2003, Exp Mol Med. 35(1):30-7.

Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K and Friedman E. 应激激活蛋白激酶p38 α和JNK1通过磷酸化稳定p21(Cip1). 2002, J Biol Chem. 277(33):29792-802.

Lim S, Jin K and Friedman E. Mirk蛋白激酶由MKK3激活，并作为hnf1 α的转录激活因子发挥作用. 2002, J Biol Chem. 277(28):25040-6.

CONFERENCES AND PRESENTATIONS

Jin K, HOXB7蛋白通过激活脂肪细胞串扰中的CCL5/CCR5通路促进乳腺癌细胞生长, April 5-10, Sandiego, CA 2024.

Jin K, CXCL1在ESR1突变乳腺癌细胞与淋巴内皮细胞之间的串扰中的作用, April 14-19, Orlando, FL, 2023.

Jin K, Reparixin, CXCR1/2抑制剂联合CDK4/6抑制剂可减轻内分泌抵抗性乳腺癌的生长和转移, April 8-13, New Orleans, LA, 2022 (Invited talk)

Jin K, HOXB7, 三阴性乳腺癌进展中的关键转录调控因子, Virtual Meeting, April 10-15, 2021

Jin K. 基质成分与内分泌抵抗性乳腺癌之间通过分泌因子的串扰促进肿瘤生长和转移. AACR Annual Meeting, Chicago IL, April 14-18, 2018.

Jin K. 基质成分与内分泌抵抗性乳腺癌之间通过分泌因子的串扰促进肿瘤生长和转移. SUNY Albany, CRC Research Seminar (invited talk).

Jin K. 基质成分与内分泌抵抗性乳腺癌之间通过分泌因子的串扰促进肿瘤生长和转移. 8th Annual Research Forum, Albany College of Pharmacy and Health Sciences, Albany NY, January 27, 2018 (invited talk).

HONORS, AWARDS, AND APPOINTMENTS 

Preclinical Catalyst Program Reviewer, Breast Cancer Now (UK)

PROFESSIONAL ORGANIZATION MEMBERSHIPS

美国癌症研究协会活跃会员